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In the context of tuberculosis (TB) resurgence, isoni-
azid preventive therapy (IPT) is increasingly promoted, but
concerns about the risk for development of isoniazid-resist-
ant tuberculosis may hinder its widespread implementation.
We conducted a systematic review of data published since
1951 to assess the effect of primary IPT on the risk for iso-
niazid-resistant TB. Different definitions of isoniazid resist-
ance were used, which affected summary effect estimates;
we report the most consistent results. When all 13 studies
(N = 18,095 persons in isoniazid groups and N = 17,985
persons in control groups) were combined, the summary
relative risk for resistance was 1.45 (95% confidence inter-
val 0.85–2.47). Results were similar when studies of HIV-
uninfected and HIV-infected persons were considered
separately. Analyses were limited by small numbers and
incomplete testing of isolates, but findings do not exclude
an increased risk for isoniazid-resistant TB after IPT. The
diagnosis of active TB should be excluded before IPT.
Continued surveillance for isoniazid resistance is essential. 
Tuberculosis (TB) has reemerged as a major threat toglobal public health. Its incidence is rising, particular-
ly in countries with a high HIV prevalence (1). HIV-infect-
ed persons have an increased risk for reactivated latent TB
infection (2), of having new TB infection progress rapidly
to active disease (3,4), and of dying during a TB episode
(5).
Since current TB control methods appear inadequate to
prevent the rise in TB incidence among HIV-infected per-
sons in settings with high TB prevalence (6), additional
measures are required. Studies in the late 1980s and 1990s
found that TB “preventive therapy” (treatment of latent TB
infection) reduced TB incidence among HIV-infected per-
sons, at least among those with positive tuberculin skin test
results (7). However, despite recommendations from the
World Health Organization (WHO) and the Joint United
Nations Programme on HIV/AIDS in 1998 (8), TB preven-
tive therapy has not been widely adopted. One obstacle to
more widespread use is the concern that using isoniazid
monotherapy to treat latent TB infection could promote
isoniazid-resistant TB; a literature review in 1970 conclud-
ed that, since the introduction of isoniazid in 1952, no evi-
dence existed to support this conclusion (9).
Since then, a number of placebo-controlled trials of iso-
niazid preventive therapy (IPT) have been conducted,
mostly among HIV-infected persons. We carried out a sys-
tematic review of studies (in both the pre-HIV and the HIV
era) that compared those who received IPT to an untreated
group and reported data on resistance to isoniazid, aiming
to assess the effect of primary IPT on the risk of develop-
ing isoniazid-resistant TB.
Methods
Identification and Selection of Studies
We searched 5 electronic databases (PubMed, Embase,
Popline, National Library of Medicine Gateway, Cochrane
Library) to identify studies of IPT published in English,
French, or Spanish from 1951 to October 2003. Thesaurus
and free-text terms were used in various combinations,
depending on the requirements of each database (details
available on request). We also searched by hand the refer-
ence lists in all identified publications and recent system-
atic reviews (7,10–12). 
We reviewed the full text of all studies evaluating the
effectiveness of primary IPT (given to persons with no
history of TB), applying the following inclusion criteria: 1)
compared incidence of TB in persons receiving isoniazid
monotherapy versus those receiving no preventive thera-
py; 2) randomized controlled trial (RCT) or cohort study
designs; and 3) results of susceptibility testing of positive
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cultures presented for both isoniazid and control groups, so
the proportion of resistant strains could be ascertained in
each group. We excluded studies conducted only in chil-
dren (among whom microbiologic confirmation is less
common), studies of secondary preventive therapy, and
studies, or subgroups within studies, of persons with
“recently active disease,” many of whom had previously
received isoniazid.
Data were extracted in duplicate by 2 investigators
independently, using a standardized data-collection form.
Data included study details (study population and size,
design, intervention drug regimen, outcomes recorded)
and quality measures (e.g., generation and concealment of
allocation sequences, blinding, duration of and loss to fol-
low-up).
Statistical Analysis
We estimated the incidence of TB caused by isoniazid-
resistant strains separately for the isoniazid and control
group of each study by dividing the number of persons with
isoniazid-resistant TB by the total number of persons in that
group. We chose the incidence of isoniazid-resistant TB in
preference to the proportion of culture-positive TB cases
that were isoniazid resistant because incidence better repre-
sents the impact (and risk for transmission) of resistant dis-
ease at the population level. Also, comparison of the
proportion of resistant isolates between groups is compli-
cated if the study population includes persons who have
latent TB infection with an isoniazid-resistant organism. In
the group receiving isoniazid, preventive therapy will
decrease the number of reactivated TB cases attributable to
isoniazid-susceptible strains but will have less effect on
resistant strains, which will increase the proportion of
resistant strains among subsequent cases of active TB. As a
result, the proportion of isoniazid-resistant active TB cases
will be higher in the isoniazid group than in the control
group, even if isoniazid does not promote new resistance.
The analysis involved a number of assumptions, sum-
marized in Table 1. In studies in which not all TB patients
underwent resistance testing, we assumed that isolates test-
ed were a random sample of all TB cases and multiplied
the total number of TB cases by the proportion of isoni-
azid-resistant cases in the sample to estimate the total num-
ber of isoniazid-resistant cases. For example, if 1,000
persons were randomly assigned to isoniazid therapy,
active TB developed in 50, 40 of these were tested, and 8
(20%) of 40 had isoniazid-resistant isolates, we then esti-
mated a total of 10 (50 × 0.2) resistant TB cases and an
incidence of isoniazid-resistant TB of 10 per 1,000 per-
sons. 
Relative risks (RR) for resistant TB in the isoniazid
group compared to the control group were calculated for
each study. The extra variation incurred by sampling iso-
lates for resistance was incorporated into the 95% confi-
dence intervals (CIs) of each RR. The RR could be written
as the product of 2 ratios (the ratio of TB incidence in
exposed/unexposed multiplied by the ratio of the propor-
tion of resistant cases in the sample tested for the
exposed/unexposed). Thus, the log RR could be expressed
as the sum of the logs of these ratios, and the variance of
the log RR could be calculated by a double application of
a standard formula (details available on request). When no
resistant cases were found in 1 of the 2 groups, we added
0.5 to the numerator and denominator of both groups when
estimating the risk, and 0.1 to the numerators and denom-
inators when calculating the variance of the ratio of pro-
portions (13).
Tests of between-study heterogeneity were performed,
and meta-analyses were carried out to derive summary
RRs, by using a random-effects model when evidence of
heterogeneity was found (14). In the meta-analysis, we
first considered all studies as a single group, then consid-
ered separately studies from the pre-HIV era and studies of
HIV-infected persons; we hypothesized that HIV-infected
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persons could be at higher risk of having resistance devel-
op. When latent TB infection is treated, few organisms are
exposed to the drug (15). The risk for selection pressure
favoring a drug-resistant organism is therefore low (16)
unless persons have undiagnosed active TB and thus inad-
vertently receive monotherapy for active disease. Active
TB may be more difficult to detect among HIV-infected
persons, which could lead to a higher risk for undiagnosed
active disease.
Sensitivity analyses primarily consisted of excluding
from meta-analyses studies a) that had zero resistant cases
in a group and b) that were not RCTs. Publication bias was
investigated by using funnel plots and adjusted rank corre-
lation tests (17). All analyses were carried out in Stata ver-
sion 8.0 (Stata Corp., College Station, TX, USA).
Results
We identified 19 studies comparing primary IPT with
no treatment that reported isoniazid resistance among
adults (9,18–35). Of the 11 studies from the pre-HIV era, 4
(23–26) were excluded because resistance data from the
control group were incomplete or not reported. In 2 stud-
ies (9,19), we excluded subgroups of persons with previ-
ously active disease, for which many had received
isoniazid. Of the 8 studies among HIV-infected persons, 2
(28,29) were excluded because the total number of isolates
tested in the relevant groups could not be determined. For
1 study (33), unpublished resistance data were obtained
from the authors (P. Godfrey-Faussett, pers. comm.).
Characteristics of Included Studies
Thirteen studies were included in the analysis (Tables
2, 3), 12 RCTs and 1 retrospective cohort study. The 7 pre-
HIV era studies (N = 32,179) were mostly conducted in the
late 1950s or early 1960s in populations of persons with
radiologically-inactive TB lesions (9,19,22), persons in
communities with high TB incidence (20,21), and house-
hold contacts of TB cases (18); 1 study was of persons
with silicosis in Hong Kong in the 1980s (27). Study pop-
ulation size ranged from 225 to 15,751 patients. In most
studies, isoniazid 300 mg (or 5 mg/kg) was given daily,
although in the Greenland study (20), 400 mg was given
on 2 consecutive days each week. Duration of treatment
was 24 weeks to 2 years. All 6 studies among HIV-infect-
ed persons (N = 3,901) recruited participants from HIV
clinics or voluntary counseling and testing centers. Study
population size was 121–1,718. RCTs administered isoni-
azid for 6 months at 300 mg daily (30,31,34,35) or 900 mg
twice weekly (33); in the cohort study, an unspecified dose
was given for 9 to 12 months (32).
We could assess the method of assigning the treatment
allocation in 5 of the 12 RCTs: 2 studies (31,33) used com-
puter-generated random numbers, 2 (20,21) used random
number tables, and 1 (19) assigned by odd or even hospi-
tal number. Three RCTs reported that the treatment was
concealed: 2 used sealed envelopes (33,34), and 1 used
numbered packages containing isoniazid or matching
placebo (27). Eight RCTs were double-blinded
(18,20,21,27,30,31,33,34), although in 1 study, isoniazid
and placebo groups may have received different numbers
of tablets (34); 2 were not blinded (19,35), and 2 did not
report blinding (9,22). Loss to follow-up was reported in
11 studies: in 6, this loss was <20% in both groups (see
unabridged, online versions of Tables 2 and 3, available at
http://www.cdc.gov/ncidod/eid/vol12no05/05-0681.htm#
table2).
Tuberculosis Cases and the Proportion 
of Isoniazid-resistant Isolates
The total number of TB cases within a study ranged
from 7 to 561. In all studies combined, 564 TB cases
occurred among persons who received isoniazid, and
1,034 occurred among controls. In the 7 studies that report-
ed this information, 55%–100% of TB cases were sputum-
culture positive (20,22,27,31,32,34,35). In 4 of these
studies, >90% of culture-positive isolates underwent
resistance testing (22,27,31,35). In total, 158 persons in the
isoniazid groups and 328 in control groups had isolates
tested for resistance to isoniazid. Definitions of isoniazid
resistance varied, and the proportion of tested isolates that
were resistant ranged from 0% to 100% (Tables 2, 3, and
unabridged online versions). A total of 31 resistant isolates
were obtained from the isoniazid groups and 28 or 24
(depending on the definition of resistance) from control
groups. Of the 6 studies among HIV-infected persons, 1
found no resistant isolates in the isoniazid group (33), 2
found no resistant isolates in the control group (31,32), and
1 found no resistance in either group (30) (Table 3).
Relative Risk for Isoniazid Resistance 
and Meta-analyses
In 8 of the 12 studies in which a single definition of
resistance was used, the point estimate of RR for isoniazid
resistance in the isoniazid group compared to that of con-
trols was >1, although this result was not statistically sig-
nificant in any study (Tables 2, 3). Two alternative (and
substantially different) definitions of resistance were used
in the Greenland study, which resulted in different esti-
mates of the effect of IPT on isoniazid resistance (Table 2).
We therefore conducted 2 analyses, using each definition
of resistance for this study. By using definition (a) from the
Greenland study, the summary RR for all 13 studies com-
bined was 1.25 (95% CI 0.75–2.10) in either a random or
fixed effects model (Figure 1A) with little evidence of het-
erogeneity (Phet = 0.789). By using definition (b) from the
Greenland study, the summary RR was 1.45 (95% CI
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0.85–2.47, Figure 1B), again with little evidence of hetero-
geneity (Phet = 0.923). Summary estimates were virtually
unaltered when analyses were restricted to RCTs without
zero cells (Figure 1). We also excluded the Greenland
study from the meta-analysis to assess its overall effect on
the summary estimate. The summary RR using the remain-
ing 12 studies was similar to that obtained by using defini-
tion (b) for resistance (RR 1.43, 95% CI 0.83–2.46).
Among the 7 studies from the pre-HIV era, the summa-
ry RR for isoniazid resistance was 1.24 (95% CI
0.69–2.21) when the definition (a) from the Greenland
study was used and 1.50 (95% CI 0.82–2.73) with defini-
tion (b). The summary RR was 1.30 (95% CI 0.42–4.02)
for the 6 studies of HIV-infected persons. Little evidence
of between-study heterogeneity was found in any of these
analyses (Phet >0.5 for all). When meta-analysis of the
studies of HIV-infected persons was restricted to the 2
RCTs without zero cells (34,35), the summary RR rose
slightly to 1.42 (95% CI 0.26–7.69) in a random-effects
model, with slightly stronger evidence of heterogeneity
(Phet = 0.179). Funnel plots (Figure 2) suggested little evi-
dence of publication bias (p = 0.625 and p = 0.542 by using
definition [a] and definition [b], respectively, for the
Greenland study). 
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Discussion
Our summary RR for isoniazid-resistant TB after IPT is
not statistically significant, but the point estimate and
upper boundary of the 95% CI are consistent with an
increased risk. Our review highlights the limitations of
existing data; however, since further individually random-
ized, controlled trials of IPT would be inappropriate,
additional data of this type are unlikely to become avail-
able. 
The numbers of TB cases in the individual studies were
often small, and in 4 studies, no resistant TB cases occurred
in at least 1 of the comparison groups. Comparison of sum-
mary estimates with and without these 4 studies suggests
that adding a small number to the numerators and denomi-
nators so they could contribute to summary estimates did
not in itself affect the result. The 95% CIs for RRs in these
studies were very wide, and so their contribution to the
summary RR estimate was limited.
The summary estimate of effect was similar in HIV-
infected and HIV-uninfected persons. Screening for active
TB before enrollment could have been more rigorous in
studies among HIV-infected persons; the screening proce-
dures were not always clearly described. 
The proportion of positive cultures tested for resistance
varied from 37% to 100%; why all isolates were not tested
was not clear. The most important assumption made in the
analysis was that the proportion of resistant cases among
the isolates tested was representative of all TB cases in that
group. If investigators were not blinded to the treatment
allocation, and if persons receiving isoniazid were more
likely to have positive cultures tested for resistance, ascer-
tainment of resistance in the isoniazid group could have
increased, and thus RR could have been overestimated.
However, in 10 of the 13 studies, a placebo was used; 8
studies specified that the trial was double blinded, and (for
studies for which information was available) similar pro-
portions of culture-positive TB cases were tested from
each group. Therefore, differential ascertainment of resist-
ance is unlikely. Our estimate of the total number of isoni-
azid-resistant cases disregarded whether case-patients
TUBERCULOSIS RESEARCH
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were sputum-culture positive. Persons with isoniazid-
resistant isolates that are sputum-culture negative are less
likely to transmit disease and present less of a public health
concern. This situation is unlikely to affect our estimate of
the effect of isoniazid on the incidence of resistant disease,
but our estimate may exaggerate the public health risk. 
Study quality and review methods may have affected
the results in other ways. For example, inadequate random
assignment of HIV-infected persons could result in more
advanced immunosuppression among those in the isoni-
azid group and thus a higher probability of resistance.
However, when reported, the method of randomization in
trials of HIV-infected persons appeared adequate.
Differences in loss to follow-up between comparison
groups could affect results if those who were lost to fol-
low-up had a different probability of resistance than those
not lost. In 6 of the 11 RCTs with information, <20% were
lost to follow-up in both groups, but the loss was notice-
ably higher in the isoniazid group than for controls in 2
studies of HIV-infected persons (34,35). Publication bias
could affect the results if studies finding increased resist-
ance among persons receiving isoniazid were more likely
to be published. However, the aim of all the studies was to
investigate effectiveness of IPT, not to ascertain develop-
ment of resistance, and our analyses suggest that publica-
tion bias did not affect the summary estimate.
The methods used to test for isoniazid resistance are
now relatively standardized and based on the proportion
method in which resistance is defined as growth on medi-
um containing 0.2 µg/mL isoniazid that exceeds 1% of the
growth on control medium (36). In older studies, methods
were less standardized and were based on absolute num-
bers of colonies growing on media with various concentra-
tions of antituberculous drugs. In the Greenland study,
Isoniazid Preventive Therapy and Resistant TB
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Figure 1. Relative risk (RR) for isoniazid resistance associated
with isoniazid preventive therapy in 13 studies. A) Using definition
(a) of resistance for the Greenland study (20). B) Using definition
(b) of resistance for the Greenland study. * Excluding the 4 studies
with no resistant cases in 1 or both of the 2 groups. The squares
and horizontal lines represent the relative risk (RR) and 95% con-
fidence intervals (CIs) for each study. The diamonds represent the
summary RR and 95% CIs.
Figure 2. Funnel plots to detect publication bias for studies report-
ing the effect of isoniazid preventive therapy on risk for isoniazid-
resistant tuberculosis. The log relative risk (RR) for each study is
plotted against the standard error of the natural log (ln) of the RR.
The horizontal line indicates the (log) summary RR, and guidelines
to assist in visualizing the funnel are plotted at the 95% pseudo-
confidence limits about the summary RR estimate. A) Using defi-
nition (a) of resistance for the Greenland study (20); B) using
definition (b) of resistance for the Greenland study. 
results for resistance were presented by using 2 divergent
definitions (neither corresponding to modern methods),
and these gave quite different estimates of effect.
Definition (a) is likely to have led to an overestimation of
resistance in both groups; definition (b) is likely to have
led to an underestimation of resistance in both groups.
When this study was excluded from the analysis, the sum-
mary estimate was similar to that using definition (b),
which suggests that the estimates using definition (a) were
more anomalous.
Studies using DNA fingerprinting illustrate that in set-
tings with a high prevalence of TB, newly acquired infec-
tion is an important cause of active TB (37,38). Thus,
isoniazid-resistant TB may be newly acquired rather than
attributable to any previous IPT. However, any such effect
should be equally distributed between randomized groups
(Table 1). 
IPT is a safe, low-cost intervention that has the poten-
tial to reduce illness and death caused by TB, especially
among HIV-infected persons. The main cause of antituber-
culous drug resistance is inadequate treatment of active
TB. Therefore, any risk for a small increase in the inci-
dence of isoniazid resistance attributable to wider use of
IPT needs to be weighed against its benefit in reducing TB
incidence.
If IPT does increase the risk for isoniazid-resistant TB,
one might argue that combination regimens should be used.
Combination regimens have similar efficacy to isoniazid
alone among HIV-infected persons and are shorter, but
these regimens generally have more adverse effects (7,39),
are more expensive, and risk promoting resistance to
rifampin. We did not compare the risk for antituberculous
drug resistance with IPT versus combination regimens.
Our review highlights the paucity of available data and
does not exclude an increased risk for isoniazid-resistant
TB after IPT. IPT substantially reduces the risk for active
TB disease in persons whose tuberculin skin test is posi-
tive, and we support the expansion of its use, in line with
recent recommendations from the HIV/TB working group
of the Stop TB partnership (40). If the main reason for the
development of resistance among persons receiving IPT is
failure to diagnose active TB, our results underscore the
need for effective diagnostic strategies and tests. In accor-
dance with WHO policy, ongoing surveillance for isoni-
azid resistance is required among populations in which this
intervention is widely implemented. 
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tuberculosis
[too-ber′′ku-lo′sis]
Any of the infectious diseases of humans or other animals caused by bacteria of the genus Mycobacterium.
From the Latin tuberculum, "small swelling," the diminutive form of tuber, "lump." Tuberculosis has existed
in humans since antiquity; it is believed to have originated with the first domestication of cattle. Evidence of
tuberculosis has been shown in human skeletal remains and mummies from as early as 4000 BC.
Mycobacterium bovis bacillus Calmette-Guérin has been successfully used to immunize humans since 1921,
and treatment (rather than prevention) of tuberculosis has been possible since the introduction of streptomycin
in 1946. Hopes of completely eliminating the disease, however, have been diminished since the rise of drug-
resistant M. tuberculosis strains in the 1980s.
Sources: Dorland's illustrated medical dictionary. 30th ed. Philadelphia: Saunders; 2003; Merriam-Webster's collegiate dictionary. 11th ed.
Springfield (MA): Merriam-Webster Incorporated; 2003; and wikipedia.org
etymologia
